

Curriculum Vitae

Personal information **Béatrice PANTERNE**

Work experience

Since January 2016 FRENCH HEALTH PRODUCTS SAFETY AGENCY (ANSM - France) -Biological products Inspector – Inspection of production sites of advanced therapy medicinal products and tissue establishments according to GMP Part IV and Tissues Cells Good Practices. Tissue Cell and ATMPs Technical Referent.

2013 - 2015 FRENCH HEALTH PRODUCTS SAFETY AGENCY - Cell and tissue coordinator - Coordination of control operations implementation of studies and projects management, participation to the assessment and the biovigilance of cellular and tissue products. Implementation of external control of breast milk and practices investigation for the 35 French lactariums. In charge of the release of blood derived products for the French OMCL

1997 - 2012 FRENCH HEALTH PRODUCTS SAFETY AGENCY - Quality control of cell therapy products responsible- Equipment of cell culture, flow cytometry and PCR laboratories - Implementation of the external quality control for cell therapy products in France – Student training Preparation of Cell therapy technical chapters and monograph at European Pharmacopoeia.

Education and training

1994 Ph D in biology of the Paris XI University - Degree obtained on February 3rd, 1994 : « Regulation study of human hematopoietic progenitor cytokine receptors ».

Additional information

Publications

PLANTAMURA E., HUYGHE G., PANTERNE B., DELESALLE N., THÉPOT A., REVERDY M.-E., DAMOUR O. and AUXENFANS C. **(2012)** Validation of the BacT/ALERT[®]3D automated culture system for the detection of microbial contamination of epithelial cell culture medium. *Cell Tissue Bank*, 13: 453-459

PANTERNE B., RICHARD M.-J., SABATINI C., ARDIOT S., HUYGHE G., LEMARIE 'C., POUTHIER F. and MOUILLOT L. **(2011)**. Ten Years of External Quality Control for Cellular Therapy Products in France, Progress in Molecular and Environmental Bioengineering - From Analysis and Modeling to Technology Applications, Angelo Carpi (Ed.), ISBN: 978-953-307-268-5, InTech, Available from: <http://www.intechopen.com/articles/show/title/ten-years-of-external-quality-control-for-cellular-therapy-products-in-france>

PANTERNE B., RICHARD M.-J., SABATINI C., POUTHIER F., MOUILLOT L. et al.. **(2010)** Contrôle de qualité des greffons de sang placentaire décongelés : résultats d'une étude multicentrique. *Transfusion Clinique et biologique*, 17 : 41-46

HATZFELD A., PANTERNE B., FORTUNEL N.-O., MONIER M.-N. & HATZFELD J. **(2001)** Finibrinogen cooperates with cytokines to induce interleukin-6 receptor mRNA expression in human hematopoietic CD34+ progenitors. *Eur. Cytokine Netw.*, 12 : 172-176

DUCOS K., PANTERNE B., FORTUNEL N., HATZFELD A., MONIER M.-N. & HATZFELD J. **(2000)** p21^{cip1} mRNA Is Controlled by Endogenous Transforming Growth Factor- β in Quiescent Human Hematopoietic Stem/Progenitor Cells. *J. Cell. Physiol.*, 184 : 80-85.

FORTUNEL N., BATARD P., HATZFELD A., MONIER M.-N., PANTERNE B.,

LEBKOWSKI J. & HATZFELD J. (1998) High Proliferative Potential-Quiescent cells : a working model to study primitive quiescent hematopoietic cells. *J. Cell. Sci.*, 111 : 1867-1875.

PANTERNE B., HATZFELD A., SANSILVESTRI P., CARDOSO A., MONIER M-N., BATARD P & HATZFELD J. (1996) IL3, GM-CSF and CSF-1 modulate c-fms mRNA more rapidly in human early monocytic progenitors than in mature of transformed monocytic cells. *J. Cell Sci.*, 109 : 1795-1801

PANTERNE B., ZHOU Y-Q., HATZFELD J., LI M-L., LEVESQUE J-P., CLARK S-C. & HATZFELD A. (1993) CSF-1 control of c-fms mRNA expression in normal human bone marrow progenitors. *J. Cell Physiol.*, 155 : 282-289

PANTERNE B., HATZFELD A., ZHOU Y-Q., LI M-L., SANSILVESTRI P., CARDOSO A., LEVESQUE J-P., GINSBOURG M., BATARD P., KISELEV S. & HATZFELD J. (1993) Positive and negative controls of hematopoietic progenitor development : Models and experimental findings. *Nouv. Rev. Fr. Hematol.*, 35 : 281-283

PANTERNE B., HATZFELD J., BLANCHARD J-M., LEVESQUE J-P., BERTHIER R., GINSBOURG M. & HATZFELD A. (1992) C-fos mRNA constitutive expression by human megakaryocytes. *Oncogene*, 7 : 2341-2344.

SANSILVESTRI P., CARDOSO A., BATARD P., PANTERNE B., HATZFELD A., LIM B., LEVESQUE J-P., MONIER M-N., HATZFELD J. (1995) Early CD34^{high} cells can be separated into KIT^{high} cells in which Transforming Growth Factor (TGF- β) down-modulates c-kit dans KIT^{low} cells in which anti-TGF-b upmodulates c-kit. *Blood*, 86 : 1729-1735.

CARDOSO A., LI M-L., BATARD P., HATZFELD A., BROWN E-L., LEVESQUE J-P., SOOKDEO H., PANTERNE B., SANSILVESTRI P., CLARK S-C. & HATZFELD J. (1993) Release from quiescence of CD34⁺ CD38⁻ umbilical cord blood cells reveals their potentiality to engraft adults. *Proc. Natl. Acad. Sci. USA*, 90 : 8707-8711

LI M-L., PANTERNE B., LEVESQUE J-P., HATZFELD J. & HATZFELD A. (1992) Cryopreservative effect of leupeptin on early human bone marrow progenitors. *In Vitro Cell. Dev. Biol.*, 28A : 459-460.

Projects

Since 2018, Animation of ANSM/ABM bilateral meetings for the technical regulatory aspects for cells and tissues and biovigilance

Memberships

Other Relevant Information

Since 2017 DG-Santé Member of the Group of National Competent Authorities for Tissues and Cells at the European Commission

2013 - 2016 ANSM Member of the French Pharmacopoeia Committee for the biological products and innovative therapies

2012 - 2015 ANSM Member of the working group for innovative therapies